Home  »  Hot Stocks   »  A Lesson to Learn: AbCellera Biologics Inc. (ABCL)...

A Lesson to Learn: AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) went up by 3.19% from its latest closing price compared to the recent 1-year high of $22.63. The company’s stock price has collected 8.63% of gains in the last five trading sessions. Barron’s reported on 09/17/21 that FDA’s Call on Lilly’s Covid Drug Is Lifting a Partner’s Beaten-Down Stock

Is It Worth Investing in AbCellera Biologics Inc. (NASDAQ :ABCL) Right Now?

AbCellera Biologics Inc. (NASDAQ:ABCL) scored a price-to-earnings ratio above its average ratio, recording 17.32 x from its present earnings ratio. Opinions of the stock are interesting as 8 analysts out of 8 who provided ratings for AbCellera Biologics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $30.13, which is $18.79 above the current price. ABCL currently public float of 202.52M and currently shorts hold a 9.50% ratio of that float. Today, the average trading volume of ABCL was 2.72M shares.

ABCL’s Market Performance

ABCL stocks went up by 8.63% for the week, with a monthly jump of 7.09% and a quarterly performance of 36.84%, while its annual performance rate touched -25.61%. The volatility ratio for the week stands at 5.11% while the volatility levels for the past 30 days are set at 5.71% for AbCellera Biologics Inc. The simple moving average for the period of the last 20 days is 5.92% for ABCL stocks with a simple moving average of 5.15% for the last 200 days.

Analysts’ Opinion of ABCL

Many brokerage firms have already submitted their reports for ABCL stocks, with The Benchmark Company repeating the rating for ABCL by listing it as a “Buy.” The predicted price for ABCL in the upcoming period, according to The Benchmark Company is $27 based on the research report published on December 21st of the previous year 2021.

Piper Sandler, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $33. The rating they have provided for ABCL stocks is “Overweight” according to the report published on November 19th, 2021.

SVB Leerink gave a rating of “Outperform” to ABCL, setting the target price at $45 in the report published on January 05th of the previous year.

ABCL Trading at 17.42% from the 50-Day Moving Average

After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.94% of loss for the given period.

Volatility was left at 5.71%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares sank -1.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +47.72% upper at present.

During the last 5 trading sessions, ABCL rose by +8.63%, which changed the moving average for the period of 200-days by -25.85% in comparison to the 20-day moving average, which settled at $10.69. In addition, AbCellera Biologics Inc. saw -20.77% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ABCL starting from Thermopylae Holdings Ltd., who purchase 9,173 shares at the price of $8.05 back on Jun 14. After this action, Thermopylae Holdings Ltd. now owns 55,644,391 shares of AbCellera Biologics Inc., valued at $73,842 using the latest closing price.

Thermopylae Holdings Ltd., the 10% Owner of AbCellera Biologics Inc., purchase 54,915 shares at $8.03 during a trade that took place back on Jun 13, which means that Thermopylae Holdings Ltd. is holding 55,635,218 shares at $441,066 based on the most recent closing price.

Stock Fundamentals for ABCL

Current profitability levels for the company are sitting at:

  • +66.61 for the present operating margin

The net margin for AbCellera Biologics Inc. stands at +40.90. Equity return is now at value 19.70, with 15.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 7.70.